MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2015.08.019

Медицинская библиотека · Vaccine · 2015

Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.

Rudenko Larisa, Kiseleva Irina, Stukova Marina, Erofeeva Marianna, Naykhin Anatoly, Donina Svetlana, Larionova Natalie, Pisareva Maria, Krivitskaya Vera, Flores Jorge, Russian LAIV Trial Study Group

Клиническое исследование I фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

This study describes a double-blinded randomized placebo-controlled phase I clinical trial of A/H5N2 live attenuated influenza vaccine in healthy volunteers.

METHODS

Two doses of vaccine or placebo were administered intranasally to 30 and 10 subjects, respectively. Nasal swabs were examined for vaccine shedding and local antibody responses; serum samples were tested for binding, hemagglutinating and neutralizing antibodies and peripheral blood mononuclear cells were tested for cell-mediated immune responses.

RESULTS

The vaccine was well tolerated and not associated with increased rates of adverse events or the occurrence of serious adverse events. Influenza virus was detected in nasal swabs on the first day in the majority of volunteers (93%), while 17% of volunteers tested positive on the second, none on the third day or later following the first vaccination; lower frequency of shedding was observed after the second vaccination. The vaccine was immunogenic as assessed four weeks after the second dose, with 37.9% and 48.3% of subjects seroconverting by hemagglutination inhibition and neutralization assays, respectively. An immune response was observed in 96.6% subjects that received A/H5N2 LAIV in at least one of the assays conducted. None of the placebo recipients exhibited a response in any of the assays.

CONCLUSION

The A/H5N2 vaccine was safe, well tolerated, and immunogenic in healthy adults.

TRIAL REGISTRATION: ClinicalTrials.gov NCT01719783.

Для цитирования: Rudenko Larisa, Kiseleva Irina, Stukova Marina, Erofeeva Marianna, Naykhin Anatoly, Donina Svetlana, Larionova Natalie, Pisareva Maria, Krivitskaya Vera, Flores Jorge, Russian LAIV Trial Study Group. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.. Vaccine. 2015. DOI: 10.1016/j.vaccine.2015.08.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.